



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Susumu MUTO et al.

Confirmation No.: 5597

Appl. No. : 10/516,294

Group Art Unit : 1614

(U.S. National Stage of PCT/JP03/07119)

I.A. Filed : June 5, 2003

Examiner : Gaffeo, Michel

For : NF-KB ACTIVATION INHIBITORS

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Service Window, Mail Stop AMENDMENT  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir :

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98 and supplemental to the Information Disclosure Statements filed February 24, 2006 and March 7, 2006, Applicants hereby direct the Examiner's attention to the following copending and commonly assigned U.S. Application:

U.S. Application 10/564,407, filed January 13, 2006 and entitled "Medicament for Treatment of Dermal Pigmentation"; Applicants note that this document is a national stage application PCT/JP2004/10558, which is published as WO 2005/007151 A1.

Furthermore, Applicants hereby bring the following information to the attention of the Examiner in charge of the above-identified application. Applicants note that this information was also provided in Applicants' copending and commonly assigned U.S. Application No. 10/564,407:

U.S. Patent Publication No. 2003/0083386 A1 (YUAN et al.), May 1, 2003;

WO 02/076926 A1, October 3, 2002;

WO 02/067919 A1, September 6, 2002;

Japanese Laid-open Patent Publication (KOKAI) HEI 11-21225 A, January 26, 1999, together with an English language abstract of the same (provided by esp@cenet);

European Patent Publication No. EP 1 535 610 A1, June 1, 2005; Applicants note that this document is an English language family member WO 03/103655 A1, December 18, 2003;

WO 2004/006906 A2, January 22, 2004;

BERKING, et al., American Journal of Pathology, 2001, Vol. 158, No. 3, pages 943-953;

SINGH, et al., Histology and Histopathology, 2000, Vol. 15, pages 843-849;

RECIO, et al., Cancer Research, 2002, Vol. 62, No. 22, pages 6724-6730;

European Patent Publication No. EP 1 535 609 A1, June 1, 2005; Applicants note that this document is an English language family member WO 03/103654 A1, December 18, 2003;

European Patent Publication No. EP 1 555 018 A1, July 20, 2005; Applicants note that this document is an English language family member WO 03/103657 A1, December 18, 2003;

European Patent Publication No. EP 1 514 544 A1, March 16, 2005; Applicants note that this document is an English language family member WO 03/103665 A1, December 18, 2003;

European Patent Publication No. EP 1 512 396 A1, March 9, 2005; Applicants note that this document is an English language family member WO 03/103647 A1, December 18, 2003; and


European Patent Publication No. EP 1 510 210 A1, March 2, 2005, which is an English language family member WO 03/103658 A1, December 18, 2003.

Copies of the above-noted information is attached hereto and duly listed on the attached Form PTO-1449. Furthermore, a copy of the International Search Report (in English) for International Application PCT/JP2004/010558, of which Applicants' copending and commonly assigned U.S. Application No. 10/564,407 is the U.S. National Stage, and the corresponding International Preliminary Report on Patentability (in English) are attached hereto as well. The Examiner is requested to initial the appropriate spaces on the attached Form and to return a copy of the initialed Form to Applicants with the next official communication in the present application.

Applicants note that an Office Action on the merits has not issued in the present application, and thus no fee is believed necessary to ensure consideration of the submitted material. However, if any fee is necessary for consideration of this Information Disclosure Statement, the undersigned hereby authorizes the charging of any fee necessary for the consideration of this statement, including any payment under 37 C.F.R. §1.17 (p), to Deposit Account No. 19-0089.

Should the Examiner have any questions, the Examiner is invited to contact the undersigned at the below-listed telephone number.

Respectfully Submitted,  
Susumu MUTO et al.

  
Bruce H. Bernstein  
Reg. No. 29,027 42,420

July 26, 2006  
GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191

FORM PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. P26316		Application No. 10/516,294	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (See several sheets if necessary)				Applicant Susumu MUTO et al.			
				Filing Date June 5, 2003		Group 1614	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	0 0 8 3 3 8 6	05/01/03	YUAN et al.				

FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES      NO		
2005 / 0 0 7 1 5 1	01/27/05	W.I.P.O					
02 / 0 7 6 9 2 6	10/03/02	W.I.P.O					
02 / 0 6 7 9 1 9	09/06/02	W.I.P.O					
11 - 2 1 2 2 5	01/26/99	JAPAN					
1 5 3 5 6 1 0	06/01/05	E.P.O					
2004 / 0 0 6 9 0 6	01/22/04	W.I.P.O					
03 / 1 0 3 6 5 5	12/18/03	W.I.P.O					
1 5 3 5 6 0 9	06/01/05	E.P.O					
03 / 1 0 3 6 5 4	12/18/03	W.I.P.O					
1 5 5 5 0 1 8	07/20/05	E.P.O					
03 / 1 0 3 6 5 7	12/18/03	W.I.P.O					
1 5 1 4 5 4 4	03/16/05	E.P.O					
03 / 1 0 3 6 6 5	12/18/03	W.I.P.O					
1 5 1 2 3 9 6	03/09/05	E.P.O					
03 / 1 0 3 6 4 7	12/18/03	W.I.P.O					
1 5 1 0 2 1 0	03/02/05	E.P.O					
03 / 1 0 3 6 5 8	12/18/03	W.I.P.O					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
1	English language Abstract of JP 11-21225.
2	BERKING, et al., "American Journal of Pathology," 2001, Vol. 158, No. 3, pages 943-953.
3	SINGH, et al., "Histology and Histopathology," 2000, Vol. 15, pages 843-849.
4	RECIO, et al., "Cancer Research," 2002, Vol. 62, No. 22, pages 6724-6730.

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.